Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer

被引：0
|
作者：
Iosifidou, R. [1 ]
Xepapadakis, G. [2 ]
Venizelos, V. [3 ]
Markopoulos, C. [4 ]
Papazisis, K. [5 ]
Tsoulos, N. [6 ]
Kapetsis, G. [6 ]
Giannoulakis, S. [6 ]
Paraskeva, M. [7 ]
Kaparelou, M. [8 ]
Lainakis, G. [3 ]
Fotarelli, A. [1 ]
Pavlidou, F. [1 ]
Fountzilas, E. [9 ]
Saloustros, E. [10 ]
Karageorgopoulou, S. [2 ]
Triantafillidou, S. [11 ]
Intzes, S. [12 ]
Koinis, F. [10 ]
机构：
[1] Theageneio Hosp, Thessaloniki, Greece
[2] IASO Hosp, Athens, Greece
[3] Metropolitan Hosp, Athens, Greece
[4] Athens Med Ctr, Maroussi, Greece
[5] EuroMed Clin, Thessaloniki, Greece
[6] Genekor SA, Athens, Greece
[7] Gen Hosp Rodos, Rodos, Greece
[8] Alexandra Gen Hosp, Athens, Greece
[9] St Lukes Hosp, Thessaloniki, Greece
[10] Univ Hosp Larisa, Larisa, Greece
[11] Genesis Hosp, Athens, Greece
[12] Interbalcan European Med Ctr, Thessaloniki, Greece
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.103933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P050
引用
收藏
页数：2
相关论文
共 50 条
  • [41] NEOADJUVANT IMMUNOTHERAPY IN PATIENTS WITH EARLY-STAGE, HIGH-RISK, ER+/HER2-BREAST CANCER: PHYSICIAN PRACTICES, THERAPY CHOICE, AND BARRIERS AMONG US ONCOLOGISTS
    Aggarwal, P.
    Van Doren, B.
    Jeune-Smith, Y.
    Jennings-Zhang, L.
    Bone, R. N.
    Sadeghi, S.
    Iyengar, N. M.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S335 - S335
  • [42] Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
    Cao, Lifen
    Towe, Christopher W.
    Stabellini, Nickolas
    Amin, Amanda L.
    Montero, Alberto J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Utilization of the Oncotype Dx Assay for Young Patients with Early Stage, Hormone-Receptor Positive, HER2-Negative Breast Cancer in an Integrated Health System
    Aller, Ashley
    Darbinian, Jeanne A.
    Liu, Raymond
    Kuehner, Gillian
    Savitz, Alison
    Odele, Patience
    Habel, Laurel
    Vuong, Brooke
    CANCER RESEARCH, 2023, 83 (05)
  • [44] Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease
    Gnerlich, Jennifer L.
    Deshpande, Anjali D.
    Jeffe, Donna B.
    Sweet, Allison
    White, Nick
    Margenthaler, Julie A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 208 (03) : 341 - 347
  • [45] German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER plus ) node negative (N0) and node positive (N plus ) early breast cancer
    Blohmer, J. -U.
    Kuehn, T.
    Rezai, M.
    Kuemmel, S.
    Warm, M.
    Eggemann, H.
    Friedrichs, K.
    Eiermann, W.
    BREAST, 2011, 20 : S46 - S46
  • [46] Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
    Browne, Iseult
    McLaughlin, Ronan
    Weadick, Catherine
    O'Sullivan, Shane
    Millen, Steve
    Hadi, Danial
    Bilal-Shah, Syed
    Al Sendhi, Maha
    Higgins, Michaela
    Crown, John
    Prichard, Ruth
    McCartan, Damian
    Hill, Arnold
    Connolly, Roisin
    Noonan, Sinead
    O'Mahony, Deirdre
    O'Hanlon-Brown, Ciara
    Hennessy, Bryan
    Quinn, Cecily
    Kelly, Catherine M.
    O'Reilly, Seamus
    Morris, Patrick G.
    Walshe, Janice
    CANCER RESEARCH, 2024, 84 (09)
  • [47] Comparison of OncotypeDX Recurrence Scores (RS) and MammaPrint (MP) scores, and chemotherapy indications in early-stage Estrogen Receptor positive/HER2 negative (ER-/HER2-) breast cancer
    Singh, Rishika
    Barlow, William
    Singh, Nupur
    Elliott, James
    Fine, Richard
    Berry, Michael
    Cobain, Erin
    Pusztai, Lajos
    Vidal, Gregory
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Impact of Sentinel Lymph Node Biopsy on Management of Older Women With Clinically Node-Negative, Early-Stage, ER + /HER2-, Invasive Breast Cancer: A Systematic Review and Meta-Analysis
    Daly, Gordon R.
    Dowling, Gavin P.
    Said, Mohammad
    Qasem, Yazan
    Hembrecht, Sandra
    Calpin, Gavin G.
    Alrawashdeh, Ma'en M.
    Hill, Arnold D. K.
    CLINICAL BREAST CANCER, 2024, 24 (08)
  • [49] TransNEOS: Validation of the oncotype DX recurrence score (RS) testing core needle biopsy samples from NEOS as predictor of clinical response to neoadjuvant endocrine therapy for postmenopausal estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer patients
    Yamamoto, Yutaka
    Iwata, Hiroji
    Masuda, Norikazu
    Fujisawa, Tomomi
    Toyama, Tatsuya
    Kashiwaba, Masahiro
    Ohtani, Shoichiro
    Taira, Naruto
    Sakai, Takehiko
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Akabane, Hiromitsu
    Shibahara, Yukiko
    Sasano, Hiroshi
    Yamaguchi, Takuhiro
    Sakamaki, Kentaro
    Chao, Calvin
    McCullough, Debbie
    Sugiyama, Naoko
    Ohashi, Yasuo
    CANCER RESEARCH, 2018, 78 (04)
  • [50] The HER2 I655V polymorphism and risk of breast cancer in women<age 40 years
    Montgomery, KG
    Gertig, DM
    Baxter, SW
    Milne, RL
    Dite, GS
    McCredie, MRE
    Giles, GG
    Southey, MC
    Hopper, JL
    Campbell, IG
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (10) : 1109 - 1111
12345